Appendix A.2.
Description of all studies that met the inclusion criteria.
| Study | Type of study | No. of patients | Distribution of EXT1 (%) | Time period | Average follow-up (months) | Incidence of chondrosarcoma Transformati ona | Males (%) | Anatomic location of chondrosarcoma transformation (%) |
Age of diagnosisb | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Humerus | Scapula | Ribs and spine | Ilium and pubis | Prox femur | Dist femur | Tibia and fibula | |||||||||
| Black et al. [12] | Longitudinal general population | 35 | – | 1968–1988 | 240 | 0 (0%) | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Altay et al. [5] | Case control | 92 | – | 1986–2004 | 93.6 | 10(9.2%) | 20.0 | 8.3 | 16.7 | 8.3 | 25.0 | 16.7 | 16.7 | 8.3 | 35.9 |
| Wuisman et al. [6] | Case control | 288 | – | 1972–1994 | 83.8 | 17(5.9%) | 76.5 | 6.8 | 17.2 | 13.8 | 37.9 | 17.2 | 3.4 | 3.4 | 34.0 (19–74) |
| Clement et al. [7] | Case control | 172 | 61.7 | 1996–2000 | 96 | 7(4.1%) | 85.7 | 14.1 | 28.1 | 28.1 | 14.3 | 14.3 | 0 | 0 | – |
| Legeai-Mallet et al. [4] | Case control | 175 | 41.0 | 1955–1995 | 102 | 1(0.6%) | 100 | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 35.0 |
| Exner and Suter [24] | Case control | 45 | – | 1971–2001 | 240 | 3(6.7%) | 66.7 | 0 | 33.3 | 0 | 66.7 | 0 | 0 | 0 | 25.0 (20–30) |
| Pierz et al. [25] | Case control | 43 | 36.5 | 1991–2001 | 101 | 0(0%) | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Vanhoenacker et al. [19] | Case control | 31 | 100 | 1968–1998 | 211 | 1(3.2%) | 100 | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 25.0 |
| Suzaki et al. [26] | Case control | 14 | 57.1 | 1963–1984 | 89 | 1(7.1%) | 100 | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 30.0 |
| Grimer et al.c[41] | Case control | 719 | – | ongoing | ongoing | NA | 56.0 | 8.0 | 16.0 | 8.0 | 48.0 | 8.0 | 8.0 | 4.0 | 37.4 (22–67) |
| Schmale et al. [1] | Cross-sectional | 113 | 43 | 1994 | NA | 1(0.88%) | 100 | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 41.0 |
| Ahmed et al. [13] | Cross-sectional | 184 | 44 | 2001 | NA | 46(25.1%) | 45.7 | 2.2 | 10.8 | 13.0 | 50.0 | 6.5 | 2.2 | 6.5 | 34.9 (15–77) |
| Garrison et al. [27]. | Cross-sectional | 183 | – | 1981 | NA | 35(19.1%) | 65.7 | 8.6 | 11.4 | 14.3 | 45.7 | 5.7 | 0 | 5.7 | 30.7 (15–68) |
| Voutsinas and Wynne-Davies [28] | Cross-sectional | 180 | – | 1995 | NA | 5(2.8%) | 80.0 | 20.0 | 0 | 0 | 60.0 | 0 | 20.0 | 0 | 32.0 (30–40) |
| Wicklund et al. [29] | Cross-sectional | 116 | – | 1983 | NA | 1(0.87%) | 100 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 25.0 |
| Gordon et al. [30] | Case repor | 37 | – | 1981 | 92 | 1(2.7%) | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 23.0 |
| Kivioja et al. [31] | Case repor | 184 | – | 1999 | 145 | 4(8.3%) | 50.0 | 50 | 0 | 0 | 50 | 0 | 0 | 0 | 37.7 (24–52) |
| Crandall et al. [32] | Case repor | 180 | – | 1983 | 162 | 0(0%) | NA | NA | NA | NA | NA | NA | NA | NA | NA |
- Data not available
a Result expressed as absolute number (percentage in brackets)
b Where it allows, the result is expressed as mean age (with range of ages in brackets)
NA: data not applicable because there were no chondrosarcomas in that study
c unpublished study from Mr Robert Grimer, Royal Orthopaedic Hospital in Birmingham. Data collection is still ongoing and some information unavailable.